Prevalence of thyroid nodules and its influencing factors in adult female population in Chengdu in 2017 - 2022
- VernacularTitle:2017—2022年成都地区成年女性甲状腺结节患病情况及其影响因素分析
- Author:
Yuandong LEI
1
;
Yong WEN
1
;
Wenyi LUO
1
Author Information
- Publication Type:Journal Article
- Keywords: Adult female; Thyroid nodule; Prevalence
- From: Journal of Public Health and Preventive Medicine 2024;35(5):89-92
- CountryChina
- Language:Chinese
- Abstract: Objective To investigate the prevalence of thyroid nodules and its influencing factors in adult women from 2017 to 2022 in Chengdu. Methods A total of 4 612 adult female patients with thyroid nodules in the 2nd Affiliated Hospital of Chengdu Medical College, Nuclear Industry 416 Hospital from January 2017 to December 2022 were selected and included in the study group. Among the 4 027 females without thyroid nodules diagnosed by physical examination in the hospital during the same period were matched for age and included in the control group. The differences in general data and thyroid-related serological parameters between the two groups were compared and the influencing factors of thyroid nodules and the epidemiological characteristics of thyroid nodules were analyzed. Results Increased Body mass index (BMI) (OR=1.104), serum anti-thyroglobulin antibodies (TGAb) (OR=1.150) and thyroid peroxidase antibody (TPOAb) (OR=1.143) levels, diabetes mellitus (OR=1.107) and family history of thyroid disease (OR=1.271) were risk factors for thyroid nodules; high quality of life and high education level were protective factors for thyroid nodules. Physical examination screening (59.67%) was the most common way to detect thyroid nodules. Influenced by the COVID-19 epidemi, physical examination screening in the past 3 years accounted for a lower proportion of thyroid nodules found (53.18%) than the pre-epidemic level (64.10%). Conclusion Strengthening thyroid screening and popular science popularization of thyroid nodules in key target populations is the focus of thyroid nodule prevention and treatment in Chengdu in the future.
